Travere Therapeutic
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-02-07
- Employees
- 380
- Market Cap
- -
- Website
- http://www.travere.com
- Introduction
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Clinical Trials
39
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06431893
- Locations
- 🇺🇸
Travere Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸Travere Investigational Site - Virtual Site, Morrisville, North Carolina, United States
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06247085
- Locations
- 🇺🇸
Travere Investigational Site - Virtual Site, Morrisville, North Carolina, United States
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05856760
- Locations
- 🇭🇰
Travere Investigational Site, Tsuen Wan, Hong Kong
🇺🇸Travere Investigation SIte, Clifton Park, New York, United States
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05562362
- Locations
- 🇬🇧
Travere Investigational Site, Nottingham, United Kingdom
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
- Conditions
- Immunoglobulin A NephropathyFocal Segmental Glomerulosclerosis
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 487
- Registration Number
- NCT05200871
- Locations
- 🇪🇸
Travere Investigational Site, Madrid, Spain
- Prev
- 1
- 2
- 3
- Next
News
FDA Approves Zevra Therapeutics' Miplyffa for Niemann-Pick Disease Type C, Stock Surges
The FDA has approved Zevra Therapeutics' Miplyffa for the treatment of Niemann-Pick disease type C, a rare neurodegenerative disorder.